STUB1/CHIP (STIP1 Homology And U-Box Containing Protein 1) is a 34.6 kDa U-box E3 ubiquitin ligase that serves as a critical nexus between molecular chaperones and the protein degradation machinery. By simultaneously binding Hsp70/Hsp90 via its N-terminal tetratricopeptide repeat (TPR) domain and catalyzing ubiquitin transfer via its C-terminal U-box domain, CHIP coordinates the triage decision for misfolded proteins — either refolding, ubiquitinating for proteasomal degradation, or targeting for autophagic clearance.
CHIP is encoded by the STUB1 gene on chromosome 6p11.2 and is ubiquitously expressed, with particularly high levels in the brain. As a central player in proteostasis, CHIP has been implicated in numerous neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, spinocerebellar ataxia, and hereditary spastic paraplegia.
| Attribute |
Value |
| Protein Name |
STUB1/CHIP |
| Gene Symbol |
STUB1 |
| UniProt ID |
Q9UNE7 |
| Molecular Weight |
34.6 kDa |
| Protein Length |
305 amino acids |
| Subcellular Localization |
Cytoplasm, Nucleus |
| Protein Family |
U-box E3 ubiquitin ligase family |
| Chromosomal Location |
6p11.2 |
CHIP possesses a bipartite domain architecture optimized for its dual role as cochaperone and E3 ligase:
N-terminal TPR Domain (residues 1-145):
- Contains three tetratricopeptide repeat (TPR) motifs
- Mediates high-affinity binding to Hsp70 and Hsp90 via their C-terminal EEVD motifs
- Also interacts with other cochaperones including Hsp40, Hsp90 cochaperone p23
- The TPR domain alone can suppress client protein aggregation in the absence of ligase activity
C-terminal U-box Domain (residues 227-305):
- Characteristic E3 ubiquitin ligase fold resembling the RING finger
- Catalyzes transfer of ubiquitin from E2 to substrate lysines
- U-box architecture stabilized by hydrogen bonds rather than metal coordination (unlike RING fingers)
- Confers ligase activity essential for proteasomal targeting
Central Linker Region (residues 146-226):
- Contains a coiled-coil domain for homodimerization
- CHIP functions as a homodimer, which is required for full E3 activity
- Dimerization allows coordinated substrate handover between Hsp70/90 and the U-box
CHIP functions as a triage manager for misfolded proteins, integrating chaperone and degradation pathways[@Connell2001]:
- Recognition: CHIP recognizes Hsp70/Hsp90-client complexes via TPR domain binding
- Handoff: Upon prolonged client misfolding, CHIP promotes client transfer from chaperones
- Ubiquitination: CHIP catalyzes ubiquitin conjugation to exposed lysine residues on misfolded proteins
- Degradation: Ubiquitinated clients are targeted to the 26S proteasome for degradation
- Autophagy: In some contexts, CHIP also directs clients toward selective autophagy pathways
Beyond degradation, CHIP modulates chaperone function:
- Dissociation: CHIP promotes release of clients from Hsp70/Hsp90 complexes
- Cochaperone activity: The TPR domain itself can suppress aggregation independent of ligase activity
- Regulation: CHIP expression is upregulated by heat shock factor 1 (HSF1) in response to proteotoxic stress
¶ Autophagy and Mitophagy
CHIP directly regulates selective autophagy through multiple mechanisms:
- p62/SQSTM1 interaction: CHIP ubiquitinates substrates that are subsequently recognized by p62
- Mitophagy: CHIP promotes清除 of damaged mitochondria via Parkin-dependent and independent pathways
- Aggregate clearance: CHIP-targeted aggregates can be engulfed by autophagosomes
CHIP influences multiple AD-relevant proteins:
Tau metabolism:
- CHIP directly ubiquitinates hyperphosphorylated tau, promoting its proteasomal degradation
- Loss of CHIP function leads to tau accumulation and aggregation
- CHIP expression is reduced in AD brains, correlating with tau pathology
- Genetic CHIP variants modify risk for tauopathies
APP and Aβ processing:
- CHIP promotes lysosomal degradation of APP, reducing Aβ production
- Hsp70/CHIP complexes can redirect APP from amyloidogenic to non-amyloidogenic pathways
Therapeutic implication: Enhancing CHIP activity could reduce both tau and Aβ burden simultaneously.
Alpha-synuclein clearance:
- CHIP promotes polyubiquitination and degradation of α-synuclein
- CHIP mutations are risk factors for PD susceptibility
- Overexpression of CHIP reduces α-synuclein aggregation in cellular and animal models
Mitophagy dysregulation:
- CHIP cooperates with Parkin in removing damaged mitochondria
- Impaired CHIP/Parkin mitophagy contributes to dopaminergic neuron vulnerability
- Loss-of-function CHIP variants increase PD risk
¶ Spinocerebellar Ataxia (SCA16 and SCA48)
Heterozygous mutations in STUB1 cause SCA16 and SCA48:
- Missense mutations in the U-box domain impair E3 ligase activity
- Mutations act through dominant-negative mechanisms
- Characterized by cerebellar ataxia, cognitive impairment, and pyramidal signs
- Onset typically in adulthood, with progressive course
Biallelic STUB1 mutations cause autosomal recessive HSP:
- Presents with lower limb spasticity and hyperreflexia
- Often accompanied by cognitive impairment
- Mutations disrupt CHIP's ability to ubiquitinate client proteins
- CHIP levels are altered in ALS spinal motor neurons
- CHIP dysfunction may contribute to TDP-43 and SOD1 aggregation
- The protein quality control axis (Hsp70-CHIP-proteasome) is a therapeutic target
flowchart TD
A["Misfolded Protein"] --> B["Hsp70/Hsp90 Chaperone Complex"]
B --> C["CHIP Recruitment<br/>(TPR domain)"]
C --> D{"Client refoldable?"}
D -->|"Yes"| E["Chaperone-mediated<br/>refolding"]
D -->|"No"| F["CHIP-mediated<br/>ubiquitination"]
F --> G{"Proteasome<br/>available?"}
G -->|"Yes"| H["26S Proteasome<br/>degradation"]
G -->|"No"| I["p62 recruitment<br/>Autophagy"]
I --> J["Autophagosome"]
J --> K["Lysosomal<br/>degradation"]
style A fill:#ffcdd2,stroke:#333
style H fill:#c8e6c9,stroke:#333
style K fill:#c8e6c9,stroke:#333
Small molecule approaches to boost CHIP activity are under investigation:
| Strategy |
Compound |
Status |
Notes |
| Hsp90 inhibitor + CHIP |
Geldanamycin analogs |
Preclinical |
Releases CHIP substrates for degradation |
| Hsp70 modulators |
Apoptozole, YM-1 |
Preclinical |
Enhance CHIP-substrate interactions |
| Direct CHIP activation |
Unknown |
Discovery |
Fragment-based screening underway |
| Gene therapy |
AAV-CHIP |
Preclinical |
Viral delivery to CNS |
- Selectivity: CHIP has hundreds of substrates — global enhancement may cause toxicity
- BBB penetration: Most small molecules don't cross the blood-brain barrier
- Balance: Enhancing CHIP may promote degradation of beneficial proteins
- Dimerization: CHIP requires homodimerization for activity — monomeric enhancers ineffective
- Hsp90 inhibitors (ganetespib, tanespimycin): Indirectly activate CHIP by destabilizing client proteins
- Proteostasis network modulators: Target upstream chaperone systems
- Combination therapy: CHIP enhancement + autophagy induction
- Hsp70 — Primary chaperone partner via TPR domain
- Hsp90 — Secondary chaperone partner
- p62/SQSTM1 — Autophagy receptor for CHIP ubiquitinated substrates
- Parkin — Cooperates in mitophagy
- VCP/p97 — Extracts ubiquitinated proteins from complexes